IP Library › Granted Patent US 10,653,604
Granted Patent B2
US 10,653,604 · App. 16/022,809 · Granted May 19, 2020

Combination of N-acyldipeptide derivatives and retinol, and methods of use thereof

Inventors: Ruey J. Yu (Chalfont, PA); Eugene J. Van Scott (Abington, PA)
Assignee: NEOSTRATA COMPANY, INC.
A61K8/64A61K8/671A61K9/0014A61K31/07A61K38/05A61Q19/00A61Q19/06A61Q19/08C07K5/0202C07K5/0205C07K5/0207C07K5/0606C07K5/06026C07K5/06034C07K5/06043C07K5/06052C07K5/06069C07K5/06078C07K5/06113C07K5/06147C07K5/06156C07K5/06165C07K5/06191A61K2800/10A61K2800/92A61Q5/00A61Q19/007A61Q19/008A61Q19/02Y02A50/463
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,653,604
App. No.
16/022,809
Granted
May 19, 2020
Kind
B2
Abstract

Methods of treating aging related skin changes and of increasing skin thickness with topical administration of N-acyldipeptide derivatives and retinol are described. Combinations of retinol and N-acyldipeptide derivatives, are therapeutically effective for increasing skin thickness, and for treating extrinsic and intrinsic aging and aging related skin changes, such as fine lines, wrinkles, photoaging, hyperpigmentation, laxity, age spots, lentigines, mottled skin, and cellulite.

Claims (21)

1. A composition comprising retinol and a therapeutically effective amount of a dipeptide derivative of formula (I):

R 1 -AAB-AAC-R 2    Formula (I)

or an isomer or salt thereof, and optionally a pharmaceutically or cosmetically acceptable carrier, wherein R 1 is an acyl radical having up to 9 carbon atoms; AAB is Tyr and AAC is Tyr, or AAB is Val and AAC is Ala; R 2 is OR 3 , NHR 4 , or NHNHR 5 ; R 3 is H, an alkyl, aralkyl, or aryl radical having up to 19 carbon atoms; and R 4 or R 5 is independently H, OH, an alkyl, aralkyl, or aryl radical having up to 19 carbon atoms.

2. The composition of claim 1 , wherein AAB is Tyr and AAC is Tyr.

3. The composition of claim 1 , wherein AAB is Val and AAC is Ala.

4. The composition of claim 1 , wherein the dipeptide derivative is selected from the group consisting of N-Ac-Tyr-Tyr-NH 2 , N-Ac-Tyr-Tyr-OH, N-Ac-Tyr-Tyr-OEt, N-Ac-Tyr-Tyr-NHNH 2 , N-Ac-Tyr-Tyr-NHNHAc, N-Ac-Tyr-Tyr-NHOH, N-Pr-Tyr-Tyr-NH 2 , N-Pr-Tyr-Tyr-OH, N-Pr-Tyr-Tyr-OEt, N-Pr-Tyr-Tyr-NHNH 2 , and N-Pr-Tyr-Tyr-NHNHPr.

5. The composition of claim 1 , wherein the dipeptide derivative is selected from the group consisting of N-Ac-Val-Ala-NH 2 , N-Ac-Val-Ala-OH, N-Ac-Val-Ala-NHOH, N-Pr-Val-Ala-NH 2 , and N-Pr-Val-Ala-OH.

6. The composition of claim 1 , wherein the dipeptide derivative is selected from the group consisting of N-Ac-Tyr-Tyr-NH 2 and N-Ac-Val-Ala-NH 2 .

7. The composition of claim 1 , wherein the dipeptide derivative is N-Ac-Val-Ala-NH 2 .

8. A method of treating aging related skin changes or changes associated with intrinsic or extrinsic aging, or of increasing skin thickness in a subject in need thereof, the method comprising topically administering to skin of the subject the composition of claim 1 .

9. The method of claim 8 , wherein the dipeptide derivative is selected from the group consisting of N-Ac-Tyr-Tyr-NH 2 , N-Ac-Tyr-Tyr-OH, N-Ac-Tyr-Tyr-OEt, N-Ac-Tyr-Tyr-NHNH 2 , N-Ac-Tyr-Tyr-NHNHAc, N-Ac-Tyr-Tyr-NHOH, N-Pr-Tyr-Tyr-NH 2 , N-Pr-Tyr-Tyr-OH, N-Pr-Tyr-Tyr-OEt, N-Pr-Tyr-Tyr-NHNH 2 , and N-Pr-Tyr-Tyr-NHNHPr.

10. The method of claim 8 , wherein the dipeptide derivative is selected from the group consisting of N-Ac-Val-Ala-NH 2 , N-Ac-Val-Ala-OH, N-Ac-Val-Ala-NHOH, N-Pr-Val-Ala-NH 2 , and N-Pr-Val-Ala-OH.

11. The method of claim 8 , wherein the dipeptide derivative is selected from the group consisting of N-Ac-Tyr-Tyr-NH 2 and N-Ac-Val-Ala-NH 2 .

12. The method of claim 8 , wherein the treatment is for aging related skin changes selected from the group consisting of fine lines; wrinkles; age spots; blotches; lentigines; mottled skin; laxity; photoaging; photodamage; hyperpigmentation; stretch marks; thinning of skin; cellulite; elastosis; loss or reduction of skin resiliency, elasticity, and recoilability; and abnormal or diminished synthesis of collagen, glycosaminoglycans, proteoglycans, or elastin.

13. The method of claim 8 , wherein the treatment is for aging related skin changes selected from the group consisting of fine lines; wrinkles; laxity; hyperpigmentation; age spots; lentigines; mottled skin; cellulite; and photoaging.

14. A method of treating fine lines, wrinkles, laxity, hyperpigmentation, or photoaging in a subject in need thereof, the method comprising topically administering to skin of the subject the composition of claim 1 .

15. The method of claim 14 , wherein the dipeptide derivative is selected from the group consisting of N-Ac-Tyr-Tyr-NH 2 , N-Ac-Tyr-Tyr-OH, N-Ac-Tyr-Tyr-OEt, N-Ac-Tyr-Tyr-NHNH 2 , N-Ac-Tyr-Tyr-NHNHAc, N-Ac-Tyr-Tyr-NHOH, N-Pr-Tyr-Tyr-NH 2 , N-Pr-Tyr-Tyr-OH, N-Pr-Tyr-Tyr-OEt, N-Pr-Tyr-Tyr-NHNH 2 , N-Pr-Tyr-Tyr-NHNHPr, N-Ac-Val-Ala-OH, N-Ac-Val-Ala-NHOH, N-Pr-Val-Ala-NH 2 , and N-Pr-Val-Ala-OH, or an isomer or salt thereof, and optionally a pharmaceutically or cosmetically acceptable carrier.

16. The method of claim 14 , wherein the dipeptide derivative is selected from the group consisting of N-Ac-Tyr-Tyr-NH 2 and N-Ac-Val-Ala-NH 2 .

17. A method of treating aging related skin changes or changes associated with intrinsic or extrinsic aging, or of increasing skin thickness in a subject in need thereof, the method comprising topically administering to skin of the subject a composition comprising retinol and a therapeutically effective amount of N-Ac-Val-Ala-NH 2 , or an isomer or salt thereof, and optionally a pharmaceutically or cosmetically acceptable carrier.

18. The method of claim 17 , wherein the treatment is for aging related skin changes selected from the group consisting of fine lines; wrinkles; age spots; blotches; lentigines; mottled skin; laxity; photoaging; photodamage; hyperpigmentation; stretch marks; thinning of skin; cellulite; elastosis; loss or reduction of skin resiliency, elasticity, and recoilability; and abnormal or diminished synthesis of collagen, glycosaminoglycans, proteoglycans, or elastin.

19. The method of claim 17 , wherein the method is for treating fine lines, wrinkles, laxity, hyperpigmentation, or photoaging.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2018
From: YU, RUEY J., PHD; VAN SCOTT, EUGENE J.
To: NEOSTRATA COMPANY, INC.
Reel/Frame 046235/0659 →
Continuity (8)
Continuation 15407474 · Jan 17, 2017
Continuation 15171601 · Jun 2, 2016
Continuation 14718317 · May 21, 2015
Division 14354711
Provisional Application 61582675 · Jan 3, 2012
Provisional Application 61554724 · Nov 2, 2011
Provisional Application 61552751 · Oct 28, 2011
Related Publication 20180303741A1 · Oct 25, 2018